Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 20/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

57%

4 trials in Phase 3/4

Results Transparency

100%

5 of 5 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

Phase 4

3(60.0%)

Phase 3

1(20.0%)

Phase 2

1(20.0%)

5Total

Phase 4(3)

Phase 3(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06098079Phase 4Active Not Recruiting

Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)

Role: lead

NCT06090461Completed

Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)

Role: lead

NCT02037893Phase 2Completed

Four Arm Safety & Efficacy With Antipyrine and Benzocaine Otic Solution in Children With Acute Otitis Media

Role: lead

NCT06089824Completed

Drug Utilisation of Mysimba/Contrave

Role: lead

NCT03338920Phase 3Terminated

Study to Assess the Safety and Efficacy of ONZETRA® Xsail® for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents

Role: lead

NCT01086358Phase 4Completed

Does Treximet Improve Productivity and Patient Satisfaction Due to Sustained Response and Consistency of Response?

Role: collaborator

NCT02353299Phase 4Completed

Assess the Effect of Zolpidem, Silenor & Placebo on Arousability, Ataxia/Balance & Cognition in Healthy Volunteers

Role: lead

All 7 trials loaded